---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-242808"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:36:26.588263+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lyell to acquire ImmPACT Bio for $30M cash + 37.5M shares; discontinues LYL797, LYL845

## Summary
- Upfront consideration: $30M cash (adjusted for ImmPACT's ~$16M cash) and 37.5M Lyell shares.
- Contingent consideration: up to 12.5M additional shares on clinical/regulatory milestone + low single-digit US royalty on IMPT-314.
- Pipeline prioritization: discontinuation of LYL797 (ROR1 CAR T), LYL845 (TIL), and preclinical TIL programs.
- Focus on IMPT-314 (dual CD19/20 CAR T) and LYL119 (next-gen ROR1 CAR T); pivotal trial for IMPT-314 expected 2025.
- Cash runway post-close into 2027; transaction expected to close Q4 2024 subject to HSR clearance.

## SEC filing metadata
- accession: 0001193125-24-242808
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/0001193125-24-242808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/d881076d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-242808
- JSON: https://secwatch.observer/filing/0001193125-24-242808.json
- Plain text: https://secwatch.observer/filing/0001193125-24-242808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.